沃华医药(002107) - 2016 Q1 - 季度财报

Revenue and Profitability - Revenue for the first quarter reached ¥131,704,277.86, an increase of 15.22% compared to ¥114,311,744.13 in the same period last year[9] - Net profit attributable to shareholders decreased by 27.25% to ¥15,612,253.97 from ¥21,459,625.34 year-on-year[9] - Basic and diluted earnings per share decreased by 33.33% to ¥0.04 from ¥0.06 in the same period last year[9] - The net profit attributable to shareholders for the first half of 2016 is expected to be between 20.33 million and 40.66 million CNY, representing a decrease of 50% compared to the same period in 2015[20] Cash Flow and Assets - Net cash flow from operating activities fell by 38.49% to ¥17,161,318.35, down from ¥27,900,121.47 in the previous year[9] - Total assets at the end of the reporting period were ¥675,721,909.57, reflecting a 1.12% increase from ¥668,227,952.48 at the end of the previous year[9] - The weighted average return on net assets improved to 3.23%, up from 2.86% year-on-year[9] Receivables and Prepayments - Prepayments increased by 105.96% to ¥2,594,306.31 due to higher material payments during the reporting period[18] - Other receivables rose by 57.44% to ¥19,308,634.54, attributed to an increase in petty cash[18] Taxation and Expenses - Income tax expenses for the period increased by 224.30% to ¥2,743,510.89 due to a rise in taxable income[18] - Marketing expenses have risen as the company enhances its market development efforts and expands product sales coverage[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,967[13] Market Competition - The company is facing intensified competition in the pharmaceutical market due to a slowdown in economic development, prompting increased marketing investments[20]